Juvenile xanthogranuloma versus langerhans cell histiocytosis (Histiocytosis X)

1999 ◽  
Vol 18 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Rossitza Lazova ◽  
Philip E. Shapiro
2008 ◽  
Vol 35 ◽  
pp. 50-54 ◽  
Author(s):  
Don T. Tran ◽  
Gregory M. Wolgamot ◽  
John Olerud ◽  
Stan Hurst ◽  
Zsolt Argenyi

Author(s):  
Maurizio Aricò ◽  
Cor van den Bos ◽  
Sheila Weitzman

This chapter summarizes the clinical spectrum of the histiocytic disorders—Langerhans cell histiocytosis (LCH), haemophagocytic lymphohistiocytosis (HLH), and some uncommon histiocytic disorders, including juvenile xanthogranuloma (JXG) and Rosai–Dorfman disease—as well as the current diagnostic and therapeutic approaches in these diseases. Multiple activating mutations in the RAS–RAF–MEK–ERK pathway have recently been described in LCH. Their role in the pathophysiology of the disorder and in targeted therapy is reviewed. This chapter explains the differences between primary and secondary HLH, and reviews the genetic abnormalities playing a role in both forms of HLH.


2001 ◽  
Vol 26 (5) ◽  
pp. 391-394 ◽  
Author(s):  
P. H. Hoeger ◽  
C. Diaz ◽  
M. Malone ◽  
J. Pritchard ◽  
J. I. Harper

2007 ◽  
Vol 51 (3) ◽  
pp. 480-482 ◽  
Author(s):  
Pio Zeppa ◽  
Immacolata Cozzolino ◽  
Maria Russo ◽  
Pietro Tullio Cataldo ◽  
Antonio Vetrani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document